Colorectal Cancer
Conditions
Brief summary
Purpose: The purpose of this study is to determine the feasibility and safety of using small beads (70-150 micron in place of 100-300 micron) to deliver chemotherapy into the liver to treat patients with liver lesions from colorectal cancer. The beads (LC-Bead M1) will be loaded with irinotecan (DEBIRI-M1), and used to administer transarterial chemoembolization (TACE). Eligibility: Patients with liver cancer from colorectal cancer. Study Overview/ Treatment: DEBIRI, loaded with irinotecan, is a device that utilizes tiny beads (70-150 microns) to deliver chemotherapy agents into liver tumor(s) via the hepatic artery. This device allows for continuous release of irinotecan into the liver tumor tissue(s) causing necrosis of the targeted tumor(s). The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. Response to therapy will be evaluated monthly by clinic visits and blood tests (to include assessment of liver function and tumor markers) and by imaging (usually MRIs) every 1-2 months. Patients will be on study for 6 months after which they will be exited from the study and followed for survival. Once exited from the study they will continue to be eligible to receive DEBIRI, should it be recommended.
Interventions
DRUGDEBIRI
Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
DEVICELC Bead M1
The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
PROCEDURETACE
TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
Sponsors
Yale University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Patients with a diagnosis of colorectal cancer with hepatic metastases who have failed or are intolerant to at least one systemic chemotherapy or liver directed therapy. 1. The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at study entry. 2. The patient is age 18 years or older. 3. The patient has a life expectancy of \>12 weeks. 4. Patients with liver dominant disease defined as \>/=75% tumor body burden confined to the liver 5. Less than 60% liver tumor replacement 6. At least one month has elapsed since most recent prior cancer therapy with the following exception: -Chemotherapy (excluding irinotecan based regimens) may continue if there is evidence of hepatic progression on treatment providing there is no change in the therapy in the 1 month prior to DEBIRI-TACE treatment and any immediate chemotherapeutic toxicity that will complicate DEBIRI-TACE is resolved. In this case, the chemotherapy may continue because it is continuing to control the extrahepatic disease. 7. The patient has measurable disease that will be directly treated with intrahepatic therapy (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1). 8. Patients with at least one measurable liver metastases\> 2 cm. 9. Patients with patent main portal vein 10. The patient has adequate hematologic function as defined by the following criteria: -An absolute neutrophil count (ANC) \>/= 1500/mL, Hemoglobin \>/= 9.5 g/dL, and a Platelet count \>/=75,000/mL, INR \</=1.3 prior to receiving DEBIRI-TACE. 11. The patient has adequate hepatic function, as defined by the following criteria: -Total bilirubin\</= 2.0 mg/dL, Aspartate transaminase (AST) and alanine transaminase (ALT) \</= 5 x the upper limit of normal (ULN), Albumin \>2. 12. The patient has adequate renal function, as defined by the following criteria: -Serum creatinine\</=2.0. 13. The patient has a baseline international normalized ratio (INR)\<1.5. 14. The patient, if a woman of childbearing potential, has a negative pregnancy test. 15. The patient is able to give written informed consent. 16. The patient is willing and able to comply with study procedures, scheduled visits, and treatment plans.
Exclusion criteria
1. The patient has a history of another primary cancer (ie, a primary cancer not associated with the patient's current liver tumor), with the exception of (a) curatively resected nonmelanomatous skin cancer; (b) curatively treated cervical carcinoma in situ; or (c) other primary solid tumor treated with curative intent, no known active disease present, and no treatment administered during the last 3 years prior to enrollment (date of informed consent). 2. Any contraindication for hepatic embolization procedures: * Large shunt as determined by the investigator (pretesting with TcMMA not required) * Severe atheromatosis * Hepatofugal blood flow * Main portal vein occlusion (e.g. thrombus or tumor) * Any patient eligible for curative treatment (i.e. resection or radiofrequency ablation) * Patients' whose only measurable disease is within an area of the liver previously subject to radiotherapy 3. Contraindications to irinotecan: * Chronic inflammatory bowel disease and/or bowel obstruction * History of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate, lactic acid or to any of the excipients of Camptosar * Severe bone marrow failure * History of Gilbert Syndrome (specific testing not required) * Concomitant use with St John's Wort (Hypericum) * Marco-shunting noted on the hepatic angiogram. 4. The patient has untreatable bleeding diathesis. 5. The patient has complete main portal vein thrombosis with reversal of flow. 6. The patient has evidence of clinically significant peripheral vascular disease. 7. The patient has brain metastases 8. The patient has clinically significant or symptomatic extrahepatic disease, for example, an uncontrolled intercurrent illness including, but not limited to: * Ongoing or active infection requiring parenteral antibiotics * Symptomatic congestive heart failure (class II to IV of the New York Heart Association classification for heart disease) * Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months * Uncontrolled hypertension (systolic blood pressure\>150 mmHg, diastolic blood pressure\>90 mmHg, found on 2 consecutive measurements separated by a 1-week period despite adequate medical support) * Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment \[NCI-CTCAE Grade 3\] or asymptomatic sustained ventricular tachycardia) 9. The patient is pregnant or breast-feeding. 10. Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements 11. There is evidence of substance abuse or medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results 12. The patient is allergic to contrast media that cannot be readily prevented with premedication or managed. 13. Other significant medical or surgical condition, or any medication or treatment, that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation 14. The patient has peritoneal disease or ascites (greater than trace on imaging).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) | 6 months | Feasibility is defined as achieving an acceptable level of technical success in the use of DEBIRI beads treating hepatic metastases in patients with colorectal cancer. |
| Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | 6 weeks | Toxicities assessed as being at least possibly related will be recorded including system organ class, subclass, grade, frequency and time interval from DEBIRI-M1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | 24 weeks | Efficacy as assessed by radiographic tumor response using EASL amendment at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Achieving 100% tumor necrosis of lesions targeted by DEBIRI-M1. Baseline degree of tumor enhancement used as a reference. Partial Response (PR): Demonstrating greater than 50% tumor necrosis in lesions targeted by DEBIRI-M1. Stable Disease (SD): Not meeting requirements for CR or PR and not demonstrating evidence of progression of lesions targeted by DEBIRI-M1. Progressive Disease (PD): Reappearance of or increased tumor enhancement greater than 25% in lesions previously targeted by DEBIRI-M1. |
| Efficacy - Tumor Response by mRECIST | 24 weeks | Efficacy as assessed by radiographic tumor response using modified RECIST (mRECIST) criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Disappearance of any intratumoral arterial enhancement in all target lesions Partial Response (PR): At least 30% decrease in the sum of diameters of viable target lesions, taking as reference the baseline sum of the diameters of target lesions Progressive Disease (PD): At least 20% increase in sum of diameters of viable target lesions, taking as reference the smallest sum of diameters of viable target lesions since treatment started. Stable Disease (SD): Any cases that do not qualify for either PR or PD. |
| Efficacy - Tumor Response by World Health Organization (WHO) Criteria | 24 weeks | Efficacy as assessed by radiographic tumor response using WHO criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): No lesions detected for at least 4 weeks. Partial Response (PR): 50% or greater decrease in the sum of the products of diameters Stable Disease (SD): Cases that do not fit the criteria of PR or PD. Progressive Disease (PD): 25% or greater increase in the sum of the products of diameters in one or more lesions; or new lesions |
| Number of Participants With Change in Carcinoembryonic Antigen (CEA) | 6 weeks | CEA measurements pre- and post- DEBIRI treatment will be recorded to ascertain if it is predictive of survival. |
| Median Overall Survival | Up to 26 months | Median overall survival from start of therapy (DEBIRI #1) until death (or date of censor). |
| One-year Survival Percentage | 1 year | Percentage of study patients surviving after one year from initial treatment analyzed with Kaplan-Meier curve. |
| Efficacy - Tumor Response by RECIST | 24 weeks | Efficacy as assessed by radiographic tumor response using the RECIST criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Disappearance of all lesions targeted by DEBIRI-M1 Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of lesions targeted by DEBIRI-M1, taking as reference the baseline sum LD Progressive Disease (PD): At least 20% increase in sum of the LD Of lesions targeted by DEBIRI-M1, taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, of lesions targeted by DEBIRI-M1, taking as reference the smallest sum LD since treatment started |
Other
| Measure | Time frame | Description |
|---|---|---|
| Plasma Half-life of Irinotecan and SN-38 Post DEBIRI-TACE | 24 hours | Plasma half-life (t 1/2) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan. |
| Exploratory Endpoint - Angiogenesis | 24 hours | Changes in vascular endothelial growth factors (VEGF), VEGF receptors VEGFR1 and VEGFR2 pre- and post- DEBIRI treatment examined for significant effects as well as association with DEBIRI treatment. One-sample Wilcoxon signed rank test was utilized to compare whether %change of VEGF, VEGFR1, or VEGFR2 from baseline was equal to 0. For groups with non-zero percent changes, the 95% confidence intervals were provided. |
| Exploratory Endpoint -Tmax of Irinotecan and SN-38 Post DEBIRI-TACE | 24 hours | Time taken to reach maximum concentration (Tmax) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan. |
| Exploratory Endpoint -Total Drug Exposure Over Time (AUC) of Irinotecan and SN-38 Post DEBIRI-TACE | 24 hours | Total drug exposure over time (AUC) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan. |
| Exploratory Endpoint - Pharmacokinetic (PK) Profile of Irinotecan and SN-38 Post DEBIRI-TACE | 24 hours | PK analysis of irinotecan and its metabolite SN-38 in the first 10 patients enrolled on protocol including peak plasma concentration (Cmax). Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan. |
Countries
United States
Participant flow
Recruitment details
This study enrolled patients diagnosed with colorectal cancer with unresectable hepatic metastases who have failed or were intolerant to at least one line of systemic chemotherapy or liver-directed therapy. Patients were enrolled at Johns Hopkins to receive transarterial chemoembolization (TACE) therapy. The last patient completed in June 2015.
Participants by arm
| Arm | Count |
|---|---|
| DEBIRI DEBIRI: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
LC Bead M1: The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
TACE: TACE a minimally invasive procedure performed to restrict a tumor's blood supply. | 14 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Change in treatment modality | 5 |
| Overall Study | Disease progression | 5 |
| Overall Study | Lost to Follow-up | 1 |
Baseline characteristics
| Characteristic | DEBIRI |
|---|---|
| Age, Continuous | 52.5 years |
| Race/Ethnicity, Customized Non-Hispanic Black or African American | 4 Participants |
| Race/Ethnicity, Customized Non-Hispanic Unknown | 0 Participants |
| Race/Ethnicity, Customized Non-Hispanic White | 6 Participants |
| Race/Ethnicity, Customized Unknown Black or African American | 0 Participants |
| Race/Ethnicity, Customized Unknown Unknown | 1 Participants |
| Race/Ethnicity, Customized Unknown White | 3 Participants |
| Region of Enrollment United States | 14 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 14 |
| other Total, other adverse events | 14 / 14 |
| serious Total, serious adverse events | 1 / 14 |
Outcome results
Primary
Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer
Toxicities assessed as being at least possibly related will be recorded including system organ class, subclass, grade, frequency and time interval from DEBIRI-M1.
Time frame: 6 weeks
Population: 6-week toxicity report of device-related adverse events for all 14 participants. Classification and grading based on CTCAE v4.0.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Elevated ALP | 2 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Hypoalbuminemia | 1 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Abdominal pain | 3 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Anemia | 2 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Nausea | 1 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Leukopenia | 1 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | 30-day mortality | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 1-2 Adverse Events | Participants with no events | 4 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Elevated ALP | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Hypoalbuminemia | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Abdominal pain | 4 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Anemia | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Nausea | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Leukopenia | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | 30-day mortality | 0 Participants |
| DEBIRI | Safety, Defined as Demonstrating Tolerable Device-related Toxicity Profile in the Use of DEBIRI Beads Used to Treat Hepatic Metastases in Patients With Colorectal Cancer | Grade 3-4 Adverse Events | Participants with no events | 10 Participants |
Primary
Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments)
Feasibility is defined as achieving an acceptable level of technical success in the use of DEBIRI beads treating hepatic metastases in patients with colorectal cancer.
Time frame: 6 months
Population: The 14 patients received a total of 32 DEBIRI-M1 TACE procedures.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DEBIRI | Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) | 100 percentage of successful treatments |
Secondary
Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria
Efficacy as assessed by radiographic tumor response using EASL amendment at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Achieving 100% tumor necrosis of lesions targeted by DEBIRI-M1. Baseline degree of tumor enhancement used as a reference. Partial Response (PR): Demonstrating greater than 50% tumor necrosis in lesions targeted by DEBIRI-M1. Stable Disease (SD): Not meeting requirements for CR or PR and not demonstrating evidence of progression of lesions targeted by DEBIRI-M1. Progressive Disease (PD): Reappearance of or increased tumor enhancement greater than 25% in lesions previously targeted by DEBIRI-M1.
Time frame: 24 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Complete Response | 0 Participants |
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Partial Response | 3 Participants |
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Stable Disease | 4 Participants |
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Progressive Disease | 6 Participants |
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Objective response (CR + PR) | 3 Participants |
| DEBIRI | Efficacy -Tumor Response by European Association for the Study of the Liver (EASL) Criteria | Disease control rate (CR + PR + SD) | 7 Participants |
Secondary
Efficacy - Tumor Response by mRECIST
Efficacy as assessed by radiographic tumor response using modified RECIST (mRECIST) criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Disappearance of any intratumoral arterial enhancement in all target lesions Partial Response (PR): At least 30% decrease in the sum of diameters of viable target lesions, taking as reference the baseline sum of the diameters of target lesions Progressive Disease (PD): At least 20% increase in sum of diameters of viable target lesions, taking as reference the smallest sum of diameters of viable target lesions since treatment started. Stable Disease (SD): Any cases that do not qualify for either PR or PD.
Time frame: 24 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DEBIRI | Efficacy - Tumor Response by mRECIST | Complete Response | 0 Participants |
| DEBIRI | Efficacy - Tumor Response by mRECIST | Partial Response | 0 Participants |
| DEBIRI | Efficacy - Tumor Response by mRECIST | Stable Disease | 9 Participants |
| DEBIRI | Efficacy - Tumor Response by mRECIST | Progressive Disease | 4 Participants |
| DEBIRI | Efficacy - Tumor Response by mRECIST | Objective response (CR + PR) | 0 Participants |
| DEBIRI | Efficacy - Tumor Response by mRECIST | Disease control rate (CR + PR + SD) | 9 Participants |
Secondary
Efficacy - Tumor Response by RECIST
Efficacy as assessed by radiographic tumor response using the RECIST criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): Disappearance of all lesions targeted by DEBIRI-M1 Partial Response (PR): At least 30% decrease in sum of longest diameter (LD) of lesions targeted by DEBIRI-M1, taking as reference the baseline sum LD Progressive Disease (PD): At least 20% increase in sum of the LD Of lesions targeted by DEBIRI-M1, taking as reference the smallest sum LD recorded since the treatment started or appearance of one or more new lesions Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, of lesions targeted by DEBIRI-M1, taking as reference the smallest sum LD since treatment started
Time frame: 24 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DEBIRI | Efficacy - Tumor Response by RECIST | Complete Response | 0 Participants |
| DEBIRI | Efficacy - Tumor Response by RECIST | Partial Response | 1 Participants |
| DEBIRI | Efficacy - Tumor Response by RECIST | Stable Disease | 8 Participants |
| DEBIRI | Efficacy - Tumor Response by RECIST | Progressive Disease | 4 Participants |
| DEBIRI | Efficacy - Tumor Response by RECIST | Objective response (CR + PR) | 1 Participants |
| DEBIRI | Efficacy - Tumor Response by RECIST | Disease control rate (CR + PR + SD) | 9 Participants |
Secondary
Efficacy - Tumor Response by World Health Organization (WHO) Criteria
Efficacy as assessed by radiographic tumor response using WHO criteria at baseline and at 6-week imaging following TACE treatments. Complete Response (CR): No lesions detected for at least 4 weeks. Partial Response (PR): 50% or greater decrease in the sum of the products of diameters Stable Disease (SD): Cases that do not fit the criteria of PR or PD. Progressive Disease (PD): 25% or greater increase in the sum of the products of diameters in one or more lesions; or new lesions
Time frame: 24 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Complete Response | 0 Participants |
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Partial Response | 1 Participants |
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Stable Disease | 9 Participants |
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Progressive Disease | 3 Participants |
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Objective response (CR + PR) | 1 Participants |
| DEBIRI | Efficacy - Tumor Response by World Health Organization (WHO) Criteria | Disease control rate (CR + PR + SD) | 10 Participants |
Secondary
Median Overall Survival
Median overall survival from start of therapy (DEBIRI #1) until death (or date of censor).
Time frame: Up to 26 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| DEBIRI | Median Overall Survival | 18.7 months |
Secondary
Number of Participants With Change in Carcinoembryonic Antigen (CEA)
CEA measurements pre- and post- DEBIRI treatment will be recorded to ascertain if it is predictive of survival.
Time frame: 6 weeks
Population: 2 out of original 14 patients had no CEA measurements.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DEBIRI | Number of Participants With Change in Carcinoembryonic Antigen (CEA) | 6 participants |
Comparison: Multivariate Cox-regression analysis to identify independent prognostic factors for overall survival from baseline characteristics. Relative risk with 95% confidence intervals calculated as measure of association.p-value: 0.004Regression, Cox
Secondary
One-year Survival Percentage
Percentage of study patients surviving after one year from initial treatment analyzed with Kaplan-Meier curve.
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| DEBIRI | One-year Survival Percentage | 36 percentage of participants |
Other Pre-specified
Exploratory Endpoint - Angiogenesis
Changes in vascular endothelial growth factors (VEGF), VEGF receptors VEGFR1 and VEGFR2 pre- and post- DEBIRI treatment examined for significant effects as well as association with DEBIRI treatment. One-sample Wilcoxon signed rank test was utilized to compare whether %change of VEGF, VEGFR1, or VEGFR2 from baseline was equal to 0. For groups with non-zero percent changes, the 95% confidence intervals were provided.
Time frame: 24 hours
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGF (immediately post) | -2.66 % change from baseline |
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGF (24 hours post) | 6.37 % change from baseline |
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGFR1 (immediately post) | 4.02 % change from baseline |
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGFR1 (24 hours post) | -37.9 % change from baseline |
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGFR2 (immediately post) | 4.49 % change from baseline |
| DEBIRI | Exploratory Endpoint - Angiogenesis | VEGFR2 (24 hours post) | 5.51 % change from baseline |
p-value: 0.6257one-sample Wilcoxon signed rank test
p-value: 0.4143one-sample Wilcoxon signed rank test
p-value: 0.583one-sample Wilcoxon signed rank test
p-value: 0.0012one-sample Wilcoxon signed rank test
p-value: 0.1353one-sample Wilcoxon signed rank test
p-value: 0.2163one-sample Wilcoxon signed rank test
Other Pre-specified
Exploratory Endpoint - Pharmacokinetic (PK) Profile of Irinotecan and SN-38 Post DEBIRI-TACE
PK analysis of irinotecan and its metabolite SN-38 in the first 10 patients enrolled on protocol including peak plasma concentration (Cmax). Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan.
Time frame: 24 hours
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| DEBIRI | Exploratory Endpoint - Pharmacokinetic (PK) Profile of Irinotecan and SN-38 Post DEBIRI-TACE | Cmax irinotecan | 1299 ng/mL | Standard Deviation 2276 |
| DEBIRI | Exploratory Endpoint - Pharmacokinetic (PK) Profile of Irinotecan and SN-38 Post DEBIRI-TACE | Cmax SN-38 | 41.5 ng/mL | Standard Deviation 26.1 |
Other Pre-specified
Exploratory Endpoint -Tmax of Irinotecan and SN-38 Post DEBIRI-TACE
Time taken to reach maximum concentration (Tmax) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan.
Time frame: 24 hours
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| DEBIRI | Exploratory Endpoint -Tmax of Irinotecan and SN-38 Post DEBIRI-TACE | Tmax of irinotecan | .95 hours | Standard Deviation 0.77 |
| DEBIRI | Exploratory Endpoint -Tmax of Irinotecan and SN-38 Post DEBIRI-TACE | Tmax of SN-38 | 1.26 hours | Standard Deviation 0.54 |
Other Pre-specified
Exploratory Endpoint -Total Drug Exposure Over Time (AUC) of Irinotecan and SN-38 Post DEBIRI-TACE
Total drug exposure over time (AUC) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan.
Time frame: 24 hours
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DEBIRI | Exploratory Endpoint -Total Drug Exposure Over Time (AUC) of Irinotecan and SN-38 Post DEBIRI-TACE | AUC irinotecan | 5020 ng*h/mL | Standard Deviation 2138 |
| DEBIRI | Exploratory Endpoint -Total Drug Exposure Over Time (AUC) of Irinotecan and SN-38 Post DEBIRI-TACE | AUC SN-38 | 305 ng*h/mL | Standard Deviation 206 |
Other Pre-specified
Plasma Half-life of Irinotecan and SN-38 Post DEBIRI-TACE
Plasma half-life (t 1/2) of irinotecan and its metabolite SN-38 post DEBIRI-TACE in the first 10 patients enrolled on protocol. Time points assessed in protocol were pre-dose, and then 5min, 10min, 15min, 30min, 1hr, 2hr, 4hr, 6hr, and 24hr post administration of 100mg irinotecan.
Time frame: 24 hours
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| DEBIRI | Plasma Half-life of Irinotecan and SN-38 Post DEBIRI-TACE | t 1/2 irinotecan | 5.7 hours | Standard Deviation 1.2 |
| DEBIRI | Plasma Half-life of Irinotecan and SN-38 Post DEBIRI-TACE | t 1/2 SN-38 | 8.6 hours | Standard Deviation 2.6 |